TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

NASDAQ:TXMD opened at $1.58 on Wednesday. The stock’s fifty day moving average is $1.70 and its 200 day moving average is $1.85. TherapeuticsMD has a fifty-two week low of $1.43 and a fifty-two week high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.23 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC purchased a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned about 0.21% of TherapeuticsMD as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.